RhumbLine Advisers
HCAT icon

RhumbLine Advisers’s Health Catalyst HCAT Stock Holding History

RhumbLine Advisers’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-34,519
Closed -$68.7K – 4095
2026
Q2 		$68.7K Sell
34,519
-51,077
-60% -$73.7K ﹤0.01% 3625
2026
Q1 		$109K Sell
85,596
-4,459
-5% -$8.39K ﹤0.01% 3373
2025
Q4 		$215K Sell
90,055
-6,801
-7% -$18.6K ﹤0.01% 3151
2025
Q3 		$276K Sell
96,856
-5,130
-5% -$17.6K ﹤0.01% 3051
2025
Q2 		$384K Buy
101,986
+12,127
+13% +$47.7K ﹤0.01% 2848
2025
Q1 		$407K Sell
89,859
-582
-0.6% -$3.08K ﹤0.01% 2704
2024
Q4 		$639K Buy
90,441
+1,042
+1% +$8.3K ﹤0.01% 2507
2024
Q3 		$728K Sell
89,399
-1,712
-2% -$12.4K ﹤0.01% 2453
2024
Q2 		$582K Buy
91,111
+7,589
+9% +$48.7K ﹤0.01% 2562
2024
Q1 		$629K Buy
83,522
+1,643
+2% +$15K ﹤0.01% 2521
2023
Q4 		$758K Buy
81,879
+23
+0% +$188 ﹤0.01% 2421
2023
Q3 		$828K Buy
81,856
+3,865
+5% +$46.1K ﹤0.01% 2313
2023
Q2 		$975K Sell
77,991
-9,618
-11% -$115K ﹤0.01% 2304
2023
Q1 		$1.02M Sell
87,609
-13,263
-13% -$169K ﹤0.01% 2108
2022
Q4 		$1.07M Buy
100,872
+18,680
+23% +$180K ﹤0.01% 2096
2022
Q3 		$797K Buy
82,192
+5,330
+7% +$70.6K ﹤0.01% 2265
2022
Q2 		$1.11M Buy
76,862
+23,673
+45% +$404K ﹤0.01% 2085
2022
Q1 		$1.39M Buy
53,189
+4,094
+8% +$116K ﹤0.01% 1992
2021
Q4 		$1.94M Buy
49,095
+409
+0.8% +$18.6K ﹤0.01% 1901
2021
Q3 		$2.44M Buy
48,686
+5,070
+12% +$277K ﹤0.01% 1792
2021
Q2 		$2.42M Buy
43,616
+7,133
+20% +$380K ﹤0.01% 1854
2021
Q1 		$1.71M Sell
36,483
-3,837
-10% -$186K ﹤0.01% 1980
2020
Q4 		$1.76M Buy
40,320
+982
+2% +$36.2K ﹤0.01% 1912
2020
Q3 		$1.44M Sell
39,338
-5,110
-11% -$174K ﹤0.01% 1848
2020
Q2 		$1.3M Buy
44,448
+21,423
+93% +$592K ﹤0.01% 1937
2020
Q1 		$602K Buy
23,025
+15,418
+203% +$471K ﹤0.01% 2099
2019
Q4 		$264K Buy
7,607
+261
+4% +$8.64K ﹤0.01% 2651
2019
Q3 		$232K Buy
+7,346
New +$289K ﹤0.01% 2692

Other funds holding HCAT

Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $13B AUM 14.15% 1-Year Est. Return
Nepsis Inc
Nepsis Inc Minneapolis, Minnesota $317M AUM 37.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
PGCM
Prescott Group Capital Management Tulsa, Oklahoma $1.11B AUM 20.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
71 West Capital Partners
71 West Capital Partners Boston, Massachusetts $3.06B AUM 23.06% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

RhumbLine Advisers's HCAT Position: Q3 2026 in Review

RhumbLine Advisers sold out of Health Catalyst (HCAT) in Q3 2026, closing a stake of 34,519 shares — an estimated $68.7K sold.

RhumbLine Advisers first reported a position in HCAT in Q3 2019 and held it in 28 quarters. The position peaked at $2.44M in Q3 2021. 58 funds tracked by Wall St. Rank hold HCAT as of Q3 2026.

  • RhumbLine Advisers reported no remaining Health Catalyst position as of Q3 2026 after selling out during the quarter.
  • RhumbLine Advisers sold 34,519 Health Catalyst shares in Q3 2026, an estimated $68.7K.
  • RhumbLine Advisers first reported a position in Health Catalyst in Q3 2019 and held it in 28 quarters.
  • RhumbLine Advisers's Health Catalyst position peaked at $2.44M in Q3 2021.
  • 58 funds tracked by Wall St. Rank held Health Catalyst as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.